anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses an alcoholic extract from the leaves of  Vitex nigundo  which when added to antibiotics, not only increases their activity but also helps to overcome antibiotic resistance in bacteria. The extract has distinctive analytical fingerprints as given in Fig. 1 and Fig. 2 and the marker compounds in the extract are vitexin and quercetin. Some of the phytocompounds present in the extract are derivatives of vitexin and quercetin. Extract of invention involves taking fresh leaves, washing and sterilizing them and then drying the leaves at 37°C followed by powdering, extraction with alcohol and purification on silica gel column. Significant enhancement of activity of the synthetic antibiotics, such as ciprofloxacin and amoxyclav was observed against bacteria viz.  S. aureus, E. coli, S. typhi  and  P. aeruginosa , when extract of present invention was used along with the antibiotics.
Patients receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
A bath lotion which is provided pertains to a traditional Chinese medicine preparation and is applied for the treatment of various skin diseases including psoriasis, ichthyosis, eczema, dermatoneuritis, pustule, ecthyma, leukoplakia of the vulva and condyloma acuminate, etc. as well as hair loss and thromboangitis obliterans. The components of a first preparation method comprise salt solution, willow leaves, bark of pomegranate, nux vomica, sodium sulfate, borax and sal ammoniac; the components of a secondary preparation method comprise willow leaves, bark of pomegranate, Chinese red pepper, sulfur or arsenic sulphide and nux vomica. (The bath lotion is obtained after medicines are dissolved in water). An earthen jar of auxiliary facilities for bath is a container made of non-woven fabrics materials or materials similar to non-woven fabrics to substitute bathtub for drug bath treatment or bath. The earthen jar is 1-1.9 meters long, about 25-60cm wide and 25-60cm high and the two ends are a bit lower; a square or a rectangle cut which is provided with a border with a height of 15-30cm is arranged at a place which is 10-20cm from one side or the other side of the upper end; a support is arranged in a two-layer bag on the border wall; the support is filled by air (the border wall is divided into different strip spaces which are inflated when in use and air in the spaces is exhausted when the bathtub is not in use) or other materials; and the bottom of the earthen jar is provided with a leakage hole with a fur plug.
The hours and earnings of the Unpredictable Instability arm will vary unpredictably over time. In any given period, there will be a 50% chance that she works longer hours (60) and earns more (180 cedis) and a 50% chance that she works fewer hours (12) and earns less (36 cedis).
The invention discloses purposes and related medicines of a human ZNF786 gene. For a first time, the invention discloses the application of human ZNF786 gene in tumor treatment, tumor diagnosis and medicine preparation. The invention further constructed human ZNF786 gene small interfering RNA (siRNA), human ZNF786 gene interfering nucleic acid construct, and human ZNF786 gene interference lentivirus. The invention also discloses purposes thereof. The siRNA, the nucleic acid construct comprising the siRNA, or the lentivirus can specifically inhibit human ZNF786 gene expression. Especially, the lentivirus can infect target cell with high efficiency, and can inhibit ZNF786 gene expression in the target cell with high efficiency. Therefore, tumor cell growth can be further inhibited, and tumor cell apoptosis can be promoted. The purpose and related medicine provided by the invention has important significance in tumor treatments.
The present invention relates to Mihaigao ointment and a preparation method thereof, particularly to a traditional Chinese medicine for curing gastric diseases and duodenal ulcer. Cuttlefish bone, radix glycyrrhiza, corydalis tuber and tendrilleaf fritillary bulb are ground into fine powder. Honey is heated and boiled into tender honey and mixed with the traditional Chinese medicines. The mixture is uniformly stirred to prepare semi-fluid honey ointment. In the present invention, other traditional Chinese medicines are added on the basis of the prescription, and the Mihaigao ointment can cure ulcer diseases of other symptoms and has the advantages of obvious effect, favorable pain alleviating effect, treatment of both manifestation and root cause of diseases, and no toxic or side effect. The effective rate can reach 100%.
Burnuot health practices are more common than the normal group. The data about Turkey are limited. In developing societies, there are often no protocols in intensive care. There are no teams again during intensive care. All work is done by physicians and other health workers. This may adversely affect health care workers. Intensive care science is new. The training first started in 2013. The newly graduated heavy-duty specialists can work where they do not want. The workload of the health workers working in the intensive care unit is high. We wanted to investigate burnout on healthcare workers in Turkey.
The invention provides an injectable rare earth-DNA photo-thermal hydrogel, which comprises the following components: DNA molecules with negative charges and rare earth-based nano materials with positive charges; the rare earth-based nano material with positive charges is UCNP-Au. The DNA molecule and the rare earth-based nano material form a hydrogel material with injectability, high-efficiency photothermal treatment effect and biocompatibility under the action of physical winding, hydrogen bonds and electrostatic force. Experimental results show that the photothermal efficiency of the injectable rare earth-DNA photothermal hydrogel can reach 42.67%. In addition, tumor suppression rates are increased, thereby reducing the chances of tumor recurrence and metastasis. By means of injection beside tumor, the toxic side effect of the medicine on normal tissues in the treatment process is reduced. And moreover, the degradation of the photo-thermal hydrogel in any time period can be realized by regulating and controlling the proportion of the DNA molecules and the rare earth-based nano material. The invention has simple and quick operation and low tumor recurrence and metastasis probability.
In the study, the object surface of the digestive endoscopy room is preliminarily analyzed, and several key exposure units, such as potential high-frequency touch areas such as the surface of the bed unit, are screened and defined. A fluorescence photographing system is arranged in the digestive endoscopy room, and the exposure unit before treatment is photographed with the best excitation wavelength of the fluorescent marker as the light source, to get the experimental background reference. Then, patients undergoing digestive endoscopy in the same endoscopy work unit (usually half a day) are selected. Before entering the digestive center, the hands of patients are fluorescently marked with vitamin B2 mixed hand sanitizer 1ml (vitamin B2 0.12mg/ml). Meanwhile, the process of the gastroscopy is recorded by camera for the recognition of touch behaviors. Then, the doctors and nurses give routine care and procedure. Based on the fluorescence tracing and detection methods, the indoor light source is turned off after each selected endoscopy work unit, and the fluorescence residue on the surface of key exposed units is photographed. The environmental surfaces touched by the patient are sampled by the wiping method. Then the video of the gastroscopy process is analyzed for the recognition of touch behaviors. The dosage is detected by the Fluoro Max-4® fluorophotometer (HORIBA, Japan), which is quantified as a cumulative mass (μg) over all the exposure time.
The AC-to-hip ratio was calculated by dividing the values of the abdominal (cm) and hip circumference (cm). Spinal anesthesia in the sitting position was performed in all patients using 2.4 ml 0.5% hyperbaric bupivacaine (12 mg). Intravenous ephedrine (5 mg) was given in case of persistent hypotension. The number of patients requiring ephedrine and the total amount of ephedrine used during surgery were recorded.
The mechanism by which immune stimulation increases circulating levels of HIV-1 is not known. In particular, it is uncertain whether the transient increase in plasma HIV-1 RNA is due to enhanced replication of an actively replicating pool of HIV-1, or is due instead to activation of proviral sequences in previously resting CD4+ cells. One approach to discriminate these alternatives is a "molecular pulse-chase" experiment. In this approach, drug resistant mutants would be selected by administration of Lamivudine (3TC).

Twenty subjects without prior 3TC experience will be treated with 3TC for 2 weeks. On day 14, half of the subjects will receive immunization with both the influenza and pneumococcal vaccine. 3TC will be discontinued at this time. Patients will be followed for 4 weeks after the immunization.
Patient is emailed a link containing web-based family health history tool prior to presenting for new Gynecologic Oncology appointment. Physician reviews results of patients web-based family health history tool. Subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
BACKGROUND: Currently, there are no reliable methods for predicting and preventing atrial fibrillation (AF) in its early stages. This study aimed to identify plasma proteins associated with AF to discover biomarkers and potential drug targets.
METHODS: The UK Biobank Pharma Proteomics Project examined 2923 circulating proteins using the Olink platform, forming the basis of this prospective cohort study. The UK Biobank Pharma Proteomics Project included a randomly selected discovery cohort and the consortium-selected replication cohort. The study's end point was incident AF, identified using International Classification of Diseases, Tenth Revision codes. The association between plasma proteins and incident AF was evaluated using Cox proportional hazard models in both cohorts. Proteins present in both cohorts underwent Mendelian randomization analysis to delineate causal connections, utilizing cis-protein quantitative trait loci as genetic tools. The predictive efficacy of the identified proteins for AF was assessed using the area under the receiver operating characteristic curve, and their druggability was explored.
RESULTS: Data from 38 784 participants were included in this study. Incident AF cases were identified in the discovery cohort (1894; 5.5%) within a median follow-up of 14.5 years and in the replication cohort (451; 10.6%) within a median follow-up of 14.4 years. Twenty-one proteins linked to AF were identified in both cohorts. Specifically, COL4A1 (collagen IV α-1; odds ratio, 1.11 [95% CI, 1.04-1.19]; false discovery rate, 0.016) and RET (proto-oncogene tyrosine-protein kinase receptor Ret; odds ratio, 0.96 [95% CI, 0.94-0.98]; false discovery rate, 0.013) demonstrated a causal link with AF, and RET is druggable. COL4A1 improved the short- and long-term predictive performance of established AF models, as evidenced by significant enhancements in the area under the receiver operating characteristic, integrated discrimination improvement, and net reclassification index, all with P values below 0.05.
CONCLUSIONS: COL4A1 and RET are associated with the development of AF. RET is identified as a potential drug target for AF prevention, while COL4A1 serves as a biomarker for AF prediction. Future studies are needed to evaluate the effectiveness of targeting these proteins to reduce AF risk.
Clinically relevant plasma concentrations of daptomycin have been observed to cause a significant concentration-dependent false prolongation of prothrombin time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are utilized for the assay. The possibility of an erroneously elevated PT/INR result due to interaction with a recombinant thromboplastin reagent may be minimized by drawing specimens for PT or INR testing near the time of trough plasma concentrations of daptomycin. However, sufficient daptomycin concentrations may be present at trough to cause interaction.

  


If confronted with an abnormally high PT/INR result in a patient being treated with daptomycin for injection, it is recommended that clinicians:  
1\. Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next daptomycin for injection dose (i.e., at trough concentration). If the PT/INR value obtained at trough remains substantially elevated above what would otherwise be expected, consider evaluating PT/INR utilizing an alternative method.  
2\. Evaluate for other causes of abnormally elevated PT/INR results.
Each training session consisted of a 20-minutes treadmill workout (using the motorized Ultıma Ac 3500 treadmill) followed by 20-minutes bicycle workout (Voit Yellow Collection 112u exercie bike). The intensity of training, which began at 50% to 60% of maximum heart rate (HR), was increased each week so that by week five, the children were at 75% to 80% maximum HR. The maximum HR, as recommended for children, was calculated using the formula 208 - 0.7 x (age) (Mahon et al., 2010). To ensure that the exercise intensity remained in the target HR zone during training, the child's HR was continuously monitored from the used treadmill and exercise bike monitors.
A total of 80 patients will be enrolled in the experimental arm. Three doses of sovateltide (each dose of 0.3 μg/kg body weight) will be given as an IV bolus in each patient (randomly assigned to this group) over one minute at an interval of 3 ± 1 hours on day 1, day 3, and day 6 (total dose/day: 0.9 μg/kg body weight). All patients will receive standard stroke treatment as provided by the specific hospital setup. Patients will be closely monitored for the qualifying stroke, followed for 3 months, and assessed for safety and efficacy parameters. Efforts will be made to administer the drug at the same time on days 1, 3, and 6.
As with all phenothiazine compounds, perphenazine should not be used indiscriminately. Caution should be observed in giving it to patients who have previously exhibited severe adverse reactions to other phenothiazines.

Some of the untoward actions of perphenazine tend to appear more frequently when high doses are used. However, as with other phenothiazine compounds, patients receiving perphenazine in any dosage should be kept under close supervision.

The antiemetic effect of perphenazine may obscure signs of toxicity due to overdosage of other drugs, or render more difficult the diagnosis of disorders such as brain tumors or intestinal obstruction.

A significant, not otherwise explained, rise in body temperature may suggest individual intolerance to perphenazine, in which case this product should be discontinued.

Neuroleptic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of neuroleptic drugs. Published epidemiologic studies have shown inconsistent results when exploring the association between hyperprolactinemia and breast cancer.
Since 1979 Austrian children and adolescents with acute lymphoblastic leukemia (ALL) have been treated according to protocols of the Berlin-Frankfurt-Münster (BFM) study group. The Associazione Italiana di Ematologia e Oncologia Pediatrica and BFM (AIEOP-BFM) ALL 2000 study was designed to prospectively study patient stratification into three risk groups using minimal residual disease (MRD) on two time points during the patient's early disease course. The MRD levels were monitored by detection of clone-specific rearrangements of the immunoglobulin and T‑cell receptor genes applying a quantitative polymerase chain reaction-based technique. The 7‑year event-free survival (EFS) and overall survival rates for all 608 Austrian patients treated between June 1999 and December 2009 within the AIEOP-BFM 2000 study were 84 ± 2% and 91 ± 1%, respectively, with a median observation time of 6.58 years. Event-free survival for patients with precursor B‑cell and T‑cell ALL were 84 ± 2% (n = 521) and 84 ± 4% (n = 87; p = 0.460), respectively. The MRD assessment was feasible in 94% of the patients and allowed the definition of precursor B‑cell ALL patients with a low, intermediate or high risk of relapse even on top of clinically relevant subgroups. A similar finding with respect to MRD relevance in T‑ALL patients was not possible due to the small number of patients and events. Since this pivotal international AIEOP-BFM ALL 2000 trial, molecular response to treatment has been continuously used with additional refinements to stratify patients into different risk groups in all successive trials of the AIEOP-BFM ALL study group.
PURPOSE:The titled tape transferring a drug to the skin effectively with time, having stable remedying effect, obtained by applying a pressure-sensitive adhesive layer comprising the drug, and a polymer of an acrylic acid ester, etc. and a polymer of a vinyl alkyl ether in a specific ratio to a base material. CONSTITUTION:One side of a base material such as polyethylene, etc. is coated with a pressure-sensitive adhesive layer comprising a drug such as prednisolone, methyl salicylate, etc. and 50-95wt% polymer consisting of an acrylic acid ester (e.g., 2-ethylhexyl acrylate, etc.) and/or methacrylic acid ester (e.g., butyl methacrylate, etc.) as an ingredient and 50-5wt% polymer consisting of a vinyl alkyl ether (e.g., vinyl isobutyl ether, etc.) as an an ingredient, to give the desired tape. The amount of the drug is preferably 1mug-5mg based on 1cm<3> pressure-sensitive adhesive layer.
1,214,533. Salicylic acid derivatives. LABORATOIRE CHOAY. 6 Feb., 1968 [7 Feb., 1967], No. 5923/68. Heading C2C. Novel salicylic acid derivatives of formula wherein R is one or more alkyl groups and salts with organic bases or metals are prepared by esterification of the appropriate phenol with the alkylphenylacetic acid or anhydride or halide thereof optionally followed by salt formation. (4-iso-Butylphenyl)acetyl chloride is prepared by reaction of the acid and thionyl chloride. Pharmaceutical compositions in conventional forms for oral, topical or parenteral administration and having analgesic, antipyretic and antiinflammatory activities comprise an above novel compound and a carrier therefor.
1463256 Dioxamic acid derivatives UPJOHN CO 2 June 1975 [10 June 1974] 23813/75 Heading C2C The invention comprises dioxamic acid derivatives of the Formula I wherein the NH-CO-COOR 1  group is at the 4-, 5- or 6-position with the proviso that (i) when it is at the 4-position, X is H, or X is at the 3-position and is C 1-3  alkyl; or X is at the 5- position and is halogen, C 1-3  alkoxy or CN; or X is at the 6-position and is halogen; (ii) when it is at the 5-position, X is H or X is at the 4-position and is halogen, C 1-3  alkyl or C 1-3  alkoxy, and (iii) when it is at the 6-position, X is H or X is at the 3- or 5-position and is C 1-3  alkyl; or X is at the 4-position and is C 1-3  alkyl or CN; and R 1  and R 2  are the same or different are each H, a physiologically acceptable metal or amine cation, C 1-12  alkyl, C 4-8  cycloalkyl, where m is 0 to 4 and Q is H, C 1-6  alkyl, phenyl, halogen, CF 3 , OH, NH 2 , NO 2 , COOH, CN, C 1-4  alkoxy or -NR 3 R 4 , wherein R 3  and R 4  each are H or C 1-4  alkyl, or (CH 2 ) n NR 5 R 6 , wherein n is 2, 3 or 4 and either R 5  and R 6  each are H or C 1-4  alkyl or NR 6 R 1  is a saturated heterocyclic ring of 3 to 6 carbon atoms, with the further proviso that when one of R 1  and R 2  is H or a physiologically acceptable metal or amine cation, the other one of R 1  and R 2  is not H or a physiologically acceptable metal or cation, and their preparation. The compounds are prepared by reacting the appropriate diaminobenzonitriles with compounds of the formulµ wherein Hal is halogen and Alk is C 1-3  alkyl, and if desired, transesterifying the resulting esters. 2,4-Diaminobenzonitrile is prepared by reducing 2,4-dinitrobenzonitrile, obtained by heating 2,4-dinitrobenzoic acid with benzenesulphonamide. 2,5-Diaminobenzonitrile is obtained by reducing 2-amino-5-nitrobenzonitrile with stannous chloride. Pharmaceutical compositions, suitable for administration orally, by inhalation, parenterally, or rectally, contain the above compound together with suitable pharmaceutical carriers. The compounds are used in the prophylactic treatment of sensitized humans and animals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature.
BACKGROUND: Tinnitus is the phantom perception of sound in the ears or head which may result from inflammation of the auditory pathway. A healthy diet consisting of a range of vitamins and minerals may be protective against tinnitus. This study aims to determine the association between intakes of dietary vitamins and minerals and the prevalence and incidence of tinnitus over 10 years.
METHODS: In this longitudinal cohort study of 2947 participants (aged ≥ 50 years), 935 (32%) cases of tinnitus were identified and included in prevalence analyses. The remaining 2012 participants were followed to establish 10-year incidence of tinnitus. A validated semi-quantitative food frequency questionnaire was used to determine intakes of dietary vitamins and minerals.
RESULTS: No significant associations with tinnitus prevalence were found. However, iron and zinc were significantly associated with incident tinnitus. There was a 44% (multivariate-adjusted HR: 1.44, 95% CI: 1.07-1.93) increased risk of developing incident tinnitus over 10 years with lower zinc intakes and a 35% increased risk with lower iron intakes (multivariate-adjusted HR: 1.35, 95% CI: 1.00-1.80).
CONCLUSION: Higher intakes of zinc and iron were significantly associated with lower tinnitus risk. Due to a lack of comparable high-quality data, future research studies should include robust study designs.
Recombinant human growth hormone therapy, which was introduced in the 1980s, is now routine for children with advanced chronic kidney disease (CKD) who are exhibiting growth impairment. Growth hormone usage remains variable across different centers, with some showing low uptake. Much of the focus on growth hormone supplementation has been on increasing height because of social and psychological effects of short stature. There are, however, numerous other changes that occur in CKD that have not received as much attention but are biologically important for pediatric growth and development. This article reviews the current knowledge about the multisystem effects of growth hormone therapy in pediatric patients with CKD and highlights areas where additional clinical research is needed. We also included clinical data on children and adults who had received growth hormone for other indications apart from CKD. Ultimately, having robust clinical studies which examine these effects will allow children and their families to make more informed decisions about this therapy.